Results 201 to 210 of about 3,442,266 (302)
Explaining risk in chronic conditions: the Yolŋu science of signs. [PDF]
Haynes E +3 more
europepmc +1 more source
Cutaneous Melanoma Drives Metabolic Changes in the Aged Bone Marrow Immune Microenvironment
Melanoma, the deadliest form of skin cancer, increasingly affects older adults. Our study reveals that melanoma induces changes in iron and lipid levels in the bone marrow, impacting immune cell populations and increasing susceptibility to ferroptosis.
Alexis E. Carey +12 more
wiley +1 more source
Portuguese Version of the PROMIS® Self-Efficacy for Managing Daily Activities for Patients With Chronic Conditions: Translation and Cross-Cultural Adaptation. [PDF]
Leite SJA +6 more
europepmc +1 more source
The Aging Blood: Cellular Origins, Circulating Drivers, and Therapeutic Potential
As a conduit linking all organs, the blood system both reflects and actively drives systemic aging. This review highlights how circulating pro‐aging and antiaging factors and age‐associated hematopoietic stem cell dysfunction contribute to immunosenescence and multi‐organ decline, positioning the hematopoietic system as a target for aging intervention.
Hanqing He, Jianwei Wang
wiley +1 more source
Editorial: New trends in managing obesity in primary care
Camila Medeiros da Silva Mazzeti +2 more
doaj +1 more source
Chronic Conditions and Patient-Centered Outcomes After Transcatheter Aortic Valve Intervention. [PDF]
Wessler BS +16 more
europepmc +1 more source
Natural products target the aging kidney in diabetic nephropathy by restoring the AMPK–SIRT1–Nrf2 axis, reducing oxidative stress, inflammation, fibrosis, and cellular senescence while enhancing mitochondrial biogenesis and antioxidant defenses.
Sherif Hamidu +8 more
wiley +1 more source
Outcomes of Team-Based Digital Monitoring of Patients With Multiple Chronic Conditions: Semiparametric Event Study. [PDF]
Graham R +4 more
europepmc +1 more source
This study aimed to evaluate the prognostic value of ELN2017 in predicting survival outcomes and to assess the impact of clinical and molecular factors such as age, FLT3 and NPM1 mutations, and allogeneic hematopoietic stem cell transplantation (allo‐HSCT).
Mobina Shrestha +4 more
wiley +1 more source

